| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 677-680
© 2003 British Society for Rheumatology
Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis
Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva, Switzerland and
1 Service de Rhumatologie, Hôpital Bichat, 46, rue Huchard, 75018 Paris, France
Objectives. To evaluate the association of anti-cyclic citrullinated peptide (anti-CCP) antibodies with immunoglobulin (Ig) M and IgA rheumatoid factors (RF) in discriminating between rheumatoid arthritis (RA) and other rheumatic diseases, and to determine, in a longitudinal study, whether clinical signs of disease severity are associated with the presence of these autoantibodies at the time of patient inclusion.
Methods. The presence of these three markers was determined in 196 patients with established RA, 239 non-RA controls with various rheumatic diseases (cross-sectional study) and in 27 patients with arthritis of less than 1 yr disease duration who were subsequently followed during about 8 yr (longitudinal study). At the time of follow-up, 21 of these 27 patients had RA. They were further evaluated and several clinical variables were recorded.
Results. The specificity was significantly increased (from 82–90% to 98% in the cross-sectional study) when the combination of anti-CCP antibodies with IgA RF or the combination of the three serological markers was used. An association was observed between the presence of the three autoantibodies and clinical signs of disease severity (functional disability, presence of erosions and absence of clinical remission).
Conclusions. The presence either of anti-CCP antibodies and IgA RF or of the three markers appears to be useful in the diagnosis of RA. Their association with clinical signs of disease severity at the time of patient inclusion suggests their potential usefulness as markers for prognosis.
KEY WORDS: Rheumatoid arthritis, Anti-cyclic citrullinated peptide antibodies, IgM rheumatoid factors, IgA rheumatoid factors.
Correspondence to: S. Bas, Research Laboratory, Division of Rheumatology, University Hospital, 1211 Geneva 14, Switzerland. E-mail: sylvette.bas{at}hcuge.ch
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Goeb, P. Dieude, R. Daveau, M. Thomas-L'Otellier, F. Jouen, F. Hau, P. Boumier, F. Tron, D. Gilbert, P. Fardellone, et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis Rheumatology, August 1, 2008; 47(8): 1208 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nishimura, D. Sugiyama, Y. Kogata, G. Tsuji, T. Nakazawa, S. Kawano, K. Saigo, A. Morinobu, M. Koshiba, K. M. Kuntz, et al. Meta-analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis Ann Intern Med, June 5, 2007; 146(11): 797 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S P Linn-Rasker, A H M van der Helm-van Mil, F C Breedveld, and T W J Huizinga Arthritis of the large joints--in particular, the knee--at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis Ann Rheum Dis, May 1, 2007; 66(5): 646 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bobbio-Pallavicini, R. Caporali, C. Alpini, S. Avalle, O. M Epis, C. Klersy, and C. Montecucco High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor {alpha} inhibitors in rheumatoid arthritis Ann Rheum Dis, March 1, 2007; 66(3): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lequerre, F. Jouen, M. Brazier, S. Clayssens, N. Klemmer, J.-F. Menard, O. Mejjad, A. Daragon, F. Tron, X. Le Loet, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab Rheumatology, March 1, 2007; 46(3): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S P Linn-Rasker, A H M van der Helm-van Mil, F A van Gaalen, M Kloppenburg, R R P de Vries, S le Cessie, F C Breedveld, R E M Toes, and T W J Huizinga Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles Ann Rheum Dis, March 1, 2006; 65(3): 366 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hayer, M. Tohidast-Akrad, S. Haralambous, B. Jahn-Schmid, K. Skriner, S. Trembleau, H. Dumortier, S. Pinol-Roma, K. Redlich, G. Schett, et al. Aberrant Expression of the Autoantigen Heterogeneous Nuclear Ribonucleoprotein-A2 (RA33) and Spontaneous Formation of Rheumatoid Arthritis-Associated Anti-RA33 Autoantibodies in TNF-{alpha} Transgenic Mice J. Immunol., December 15, 2005; 175(12): 8327 - 8336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. J. Harney, C. Meisel, A.-M. Sims, P. Y. Woon, B. P. Wordsworth, and M. A. Brown Genetic and genomic studies of PADI4 in rheumatoid arthritis Rheumatology, July 1, 2005; 44(7): 869 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chang, R. Yamada, A. Suzuki, T. Sawada, S. Yoshino, S. Tokuhiro, and K. Yamamoto Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis Rheumatology, January 1, 2005; 44(1): 40 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Alessandri, M Bombardieri, N Papa, M Cinquini, L Magrini, A Tincani, and G Valesini Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF{alpha} therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis, October 1, 2004; 63(10): 1218 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Vallbracht, J Rieber, M Oppermann, F Forger, U Siebert, and K Helmke Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis Ann Rheum Dis, September 1, 2004; 63(9): 1079 - 1084. [Abstract] [Full Text] [PDF]
|
|